Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with Alopecia areata in Iraq had significantly higher levels of CD4+, CD39+, and FOXP3+ Treg cells in their blood compared to healthy controls.

This paper contains author contact information and disclosures without reporting new research findings or results.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

In this study, researchers developed a new humanized mouse model for alopecia areata that highlights the role of specific immune cells and may aid in discovering new treatments for the disease.

The Fas/FasL pathway may play a role in alopecia areata.

This study found a strong positive correlation between alopecia areata burden and the Socio-Demographic Index, indicating a disproportionate impact on high-income countries, especially affecting young adults and females.

This study developed a new triamcinolone acetonide serum combined with a microneedling device, showing promise for treating alopecia areata by targeting hair follicles in a less invasive, patient-friendly way with confirmed drug solubility, compatibility, and safety.

This study found that immune-mediated destruction of bulge stem cells is a key factor in the alopecia observed in AE mice, suggesting it as a model for studying primary cicatricial alopecias, particularly lichen planopilaris.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

This study demonstrates that machine learning-assisted fabrication of PRP-incorporated microneedles effectively promotes hair regrowth in AGA mice, outperforming minoxidil and mitigating biosafety risks associated with synthetic materials.

This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.

A synthetic drug and a South American herb may help treat alopecia areata in Chinese men.

This study found that Aminexil clinical 5 significantly reduced hair loss in men and women with mild alopecia and was well tolerated with high subject satisfaction.

DNCB is highly effective for treating alopecia areata with minimal long-term side effects.

This study used bibliometric analysis to evaluate global research on AI applications in dermatology, identifying 406 relevant papers and highlighting current priorities such as machine learning for wound progression, AI in teledermatology, and applications for skin diseases.

In this study, metal-organic frameworks modified with stearic acid were used to deliver cardamonin to hair follicles, significantly promoting hair growth and cell proliferation in testosterone-challenged mice, suggesting potential benefits for androgenic alopecia treatment.

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.

This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.

This review discusses the emerging role of AMT in fibrosis and suggests that targeting AMT could offer a novel approach to treatment; it reports no new clinical results.

This review concluded that Unani medicine offers a promising holistic approach to managing androgenetic alopecia by focusing on humoral balance and follicular rejuvenation, but further scientific validation is needed for widespread clinical use.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.

This study suggests that activating AMPK to phosphorylate ZDHHC13 may enhance MC1R function and reduce melanoma risk in individuals with red hair.

In this study, researchers investigated the role of the ATX-LPA axis in asthma pathogenesis using human and mouse models and highlighted the potential for developing new ATX inhibitors as effective asthma treatments.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study investigated genetic and phenotypic characteristics of androgen insensitivity syndrome in individuals with a 46,XY karyotype, documenting a range from complete to partial insensitivity.

This study synthesized nonsteroidal ligands as second-generation androgen receptor agonists and identified three compounds with significant anabolic activity and moderate to minimal androgenic activity in vivo.

In this study, single-cell sequencing revealed clonal expansions of CD4+ and CD8+ T cells in murine and human alopecia areata, supporting the development of predictive models for human disease.

Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.